Relaxin-3 is a neuropeptide that is abundantly expressed by discrete brainstem neuron populations that broadly innervate forebrain areas rich in the relaxin-3 G-protein-coupled-receptor, RXFP3. Acute and subchronic central administration of synthetic relaxin-3 or an RXFP3-selective agonist peptide, R3/I5, increase feeding and body weight in rats. Intrahypothalamic injection of relaxin-3 also increases feeding. In this study, we developed a recombinant adeno-associated virus 1/2 (rAAV1/2) vector that drives expression and constitutive secretion of bioactive R3/I5 and assessed the effect of intrahypothalamic injections on daily food intake and body weight gain in adult male rats over 8 weeks. In vitro testing revealed that the vector rAAV1/2-fibronectin (FIB)-R3/I5 directs the constitutive secretion of bioactive R3/I5 peptide. Bilateral injection of rAAV1/2-FIB-R3/I5 vector into the paraventricular nucleus produced an increase in daily food intake and body weight gain (Po0.01, B23%, respectively), relative to control treatment. In a separate cohort of rats, quantitative polymerase chain reaction analysis of hypothalamic mRNA revealed strong expression of R3/I5 transgene at 3 months post-rAAV1/2-FIB-R3/I5 infusion. Levels of mRNA transcripts for the relaxin-3 receptor RXFP3, the hypothalamic 'feeding' peptides neuropeptide Y, AgRP and POMC, and the reproductive hormone, GnRH, were all similar to control, whereas vasopressin and oxytocin (OT) mRNA levels were reduced by B25% (P ¼ 0.051) and B50% (Po0.005), respectively, in rAAV1/2-FIB-R3/I5-treated rats (at 12 weeks, n ¼ 9/8 rats per group). These data demonstrate for the first time that R3/I5 is effective in modulating feeding in the rat by chronic hypothalamic RXFP3 activation and suggest a potential underlying mechanism involving altered OT signalling. Importantly, there was no desensitization of the feeding response over the treatment period and no apparent deleterious health effects, indicating that targeting the relaxin-3-RXFP3 system may be an effective long-term therapy for eating disorders.
INTRODUCTION
Relaxin-3 is the ancestral member of the relaxin peptide family, which includes relaxin-1, relaxin-2 and insulin-like peptides (INSL) 3, 4, 5 and 6. In their pro-form, these peptides comprise an A-and B-chain connected by a large C-chain, which is subsequently cleaved to produce the processed form with the A-and B-chains stabilized via two inter-chain and one intra-A-chain disulphide bond. Relaxin-3 was discovered in 2002 and unlike other members of this family, which are peripheral hormones, is predominantly expressed in the brain where it acts as a neuropeptide modulator. [1] [2] [3] Relaxin-3 is produced by small populations of GABA projection neurons in the brainstem of the rat and mouse, with the largest number in a tegmental nucleus, known as the nucleus incertus or nucleus O. [2] [3] [4] [5] In the rat, these neurons have widespread projections throughout the forebrain, projecting to the amygdala, hippocampus, septum and hypothalamus. [6] [7] [8] The cognate receptor for relaxin-3 is the G-protein-coupled-receptor, RXFP3. 9 The expression pattern of RXFP3 largely overlaps the distribution pattern of relaxin-3-like immunoreactivity in axons and nerve terminals. 4, 6 In situ hybridization studies detected abundant RXFP3 mRNA in the amygdala, somatosensory cortex, paraventricular nucleus (PVN) of the hypothalamus and several midline thalamic nuclei. 6, 9 The presence of RXFP3 (protein) in these areas was confirmed by autoradiography of binding studies for an 125 I-labelled relaxin-3 analogue. 6, 10 The distribution of relaxin-3/RXFP3 networks and findings from initial functional studies with synthetic relaxin-3 are consistent with a role in the control of several inter-related modalities, including stress and arousal, feeding and metabolism, and learning and memory. 4, [11] [12] [13] [14] Native relaxin-3 is also an agonist for the related receptors RXFP1 and RXFP4, albeit with lower affinity. 15, 16 Thus, to study the effects of RXFP3 modulation more precisely, selective agonists and antagonists have been designed to activate only RXFP3 (and RXFP4), and not RXFP1. The chimeric peptide, R3/I5, is B1000-fold more potent at RXFP3 than RXFP1 and comprises the A-chain of human insulin-like peptide 5 and the B-chain of human relaxin-3.
17 R3/I5 activates RXFP4 in vitro, but as the gene for RXFP4 is a pseudogene in the rat, 18 this peptide can be used for selective activation of RXFP3 in rat brain. Indeed, many studies have examined the effect of intracerebroventricular and local regional administration of synthetic relaxin-3, R3/I5 and/or an RXFP3 antagonist peptide, DR3/I5, on physiology and behaviour, as a reflection of RXFP3 activity. 12, 13, [19] [20] [21] [22] However, there are clear procedural and less obvious logistical limitations with the central 1 administration of such difficult to synthesize peptides that preclude insights into the chronic effects of RXFP3 modulation. For example, these synthetic peptides have a relatively short duration of action and any repeated administration protocol used to study chronic effects of RXFP3 modulation can affect behavioural end points being examined.
Recombinant adeno-associated viruses (rAAV) provide a means by which long-term gene expression can be achieved after a single administration and without eliciting an immune response in the host. 23, 24 rAAVs have been used extensively to express neuropeptides such as neuropeptide Y (NPY) and galanin in vivo; 25, 26 thus, we decided to utilize the rAAV vector system to express a transgene encoding R3/I5 to study the effects of chronic RXFP3 activation in vivo. We utilized a previously characterized R3/I5 expression construct, which encodes the pro-form of R3/I5, with the human insulin-like peptide 5 A-chain and H3 relaxin B-and C-chains and furin cleavage sites at the B/Aand C/A-chain junction. 17 Although the pro-form of relaxin-3 is active at RXFP1, its activity at RXFP3 has not been assessed. 27 However, it is likely that cleavage of the C-peptide is necessary for RXFP3 activity, as modifications of the C terminus of the B-chain at the junction where cleavage occurs result in a dramatic loss of peptide activity. 22 The presence of the furin cleavage sites ensures highly efficient cleavage of the C-chain as furin is a ubiquitous prohormone convertase. 28 We hypothesized that utilizing an rAAV system to chronically express R3/I5 in areas of rat brain containing abundant RXFP3 expression would alter behaviours associated with specific relaxin-3/RXFP3 signalling. Instead of being processed like a conventional neuropeptide, where the peptide is packaged in dense-core vesicles, transported along neuronal axons and dendrites and released at distant synaptic (and non-synaptic) sites, we needed to ensure that the R3/I5 peptide was secreted locally at the site of viral injection to ensure targeting of RXFP3 in the vicinity of the injection. We therefore used a viral construct whereby the FIB signal peptide is fused to the N terminus of the peptides in place of the native signal peptide. FIB is a laminar protein that is shunted down a constitutive secretory pathway in neurons and is thus secreted by the neuronal cell body. 29 Peptides/proteins with the FIB signal peptide are secreted constitutively from the neuronal soma, creating a high local concentration of peptide in the immediate environment. This rAAV construct has been utilized to direct the local secretion of galanin or NPY from neurons in the rat brain to suppress seizure activity. 25, 30 In addition, it has been demonstrated that FIB-peptide constructs with furin-processing domains are efficiently cleaved in the constitutive pathway after in vivo injection into brain regions. 31 An FIB-galanin-green fluorescent protein (GFP) fusion protein, in which the two proteins were connected by a furin cleavage sequence, was expressed in the piriform cortex of rats, where it was demonstrated that the fusion protein was cleaved and both galanin and GFP were shown to be functional in vivo. 25 Importantly, furin is present in high levels in many neuron populations, particularly those that produce neuropeptides or endocrine hormones, such as the major hypothalamic neuroendocrine neuron populations. 32, 33 It is very likely that rAAV-driven transgene expression of an FIB-R3/I5 transgene would result in local secretion of cleaved, bioactive R3/I5 peptide.
It is well established that central administration of relaxin-3 alters feeding in rats. When McGowan and co-workers 13 administered synthetic relaxin-3 intracerebroventricularly in satiated male Wistar rats, there was an increase in feeding observed over 4 h, with the strongest effect in the first hour. 13 A similar effect was observed when relaxin-3 was administered directly into the PVN, but not after administration into the lateral hypothalamus. 20 There was also an increase in feeding when R3/I5 was administered intracerebroventricularly. 22 In addition, intracerebroventricular relaxin-3 infusion for 14 days in male Wistar rats using osmotic minipumps caused sustained increases in body weight and feeding. 34 This established feeding response represents an ideal assay to establish whether the viral peptide expression system is effective in producing cleaved bioactive peptide and activation of RXFP3. In addition, this approach is designed to establish whether feeding can be regulated chronically (that is, for X8 weeks) by targeting RXFP3. We decided to target rAAV1/2 injections into the PVN, to facilitate production of R3/I5 in close proximity to the dense population of RXFP3 identified in PVN. Not only do PVN neurons contain a large population of RXFP3, but studies have also shown that there is abundant expression of furin in the hypothalamus, 32, 33 making it highly likely that the FIB-pro-R3/I5 protein will be cleaved. Results from this study have validated the application of this viral approach to this peptide system and demonstrate for the first time that feeding/food intake can be modulated chronically by RXFP3 activation in the hypothalamus.
RESULTS

Pro-relaxin-3 activity at RXFP3
Our previous studies have demonstrated that pro-relaxin-3 has full bioactivity at RXFP1, 27 but the activity at RXFP3 had not been tested. As this information was essential for the design of the viral vectors, we tested the activity of pro-relaxin-3 at RXFP3 using an established cAMP activity assay. 27 CHO-KI cells stably expressing RXFP3 were stimulated with increasing concentrations of the synthetic peptides, H3-relaxin and R3/I5 in their mature 2-chain forms, or recombinant mouse pro-relaxin-3. H3-relaxin and R3/I5 binding to RXFP3 in CHO cells is coupled to activation of the inhibitory G-protein, reflected by inhibition of forskolin-induced cAMP accumulation in CHO cell systems in vitro. 9 In this study, H3-relaxin and R3/I5 produced a dose-related inhibition of cAMP activity with similar pEC 50 (the negative logarithm of the halfmaximal effective concentration) values to those reported earlier (7.89 and 8.59, respectively). However, at concentrations up to 1 mM, mouse pro-relaxin-3 only produced B25% inhibition of forskolin-induced cAMP activity (Figure 1) . Thus, as cleavage of the C-peptide seems to be required for full biological activity of relaxin-3 peptides at RXFP3, we designed and produced an R3/I5 construct that included cleavage sites at the B/A-and C/A-chain junctions that would be cleaved in vivo.
In vitro characterization of the R3/I5 gene delivery vector For these studies, we used a vector (pCMVSportR3/I5) that coded for the H3 relaxin B-C peptide with the INSL5 A-chain and containing furin cleavage sites at the B/A-and C/A-chain junctions and the viral vector, TR-chicken b-actin (CBA)-FIB-GFP ( Figure 2) . 17, 25 From these two vectors, we constructed FIB-R3/I5, which we proposed would direct the expression of cleaved R3/I5 into the secretory pathway. The final FIB-R3/I5 coding region was cloned into pAM-DCA-EcoRI-EGFP by replacing the EGFP with FIB-R3/I5, to produce pAM-FIB-R3/I5 (Figure 2) .
This construct was first tested in an in vitro HEK293T cell expression system, used previously to test the bioactivity of recombinant relaxin peptides. 35 As the HEK293T system does not contain sufficient levels of endogenous furin to cleave the C-chain of the pro-relaxin peptides, we also expressed recombinant human furin in these cells to ensure efficient cleavage of the C-chain of pro-R3/I5. (Note: however, it has been shown that neurons contain adequate levels of furin to process peptides containing these cleavage sites.) 31 HEK293T cells were cotransfected with pCMVSportR3/I5 and the plasmid encoding human furin protease (pfurin), or with the newly constructed pAM-FIB-R3/I5 and pfurin. Cells were incubated for 48 h to allow peptide accumulation in the media, which was then collected and used to stimulate RXFP3-expressing CHO-KI cells in the cAMP activity assay. 27, 36 A 1:10 dilution of media produced a similar inhibition of cAMP activity to 100 nM H3 relaxin (Figure 3a) , indicating that bioactive R3/I5 was being produced by both constructs. We then used different dilutions of media from pCMVSportR3/I5 þ pFurin and pAM-FIB-R3/I5 þ pfurin cultures and demonstrated a dose-dependent inhibition of cAMP activity for both constructs (Figure 3b ). Importantly, media from mocktransfected cells demonstrated no activity. The activity of media from pCMVSportR3/I5 þ pfurin-transfected cells was higher than media from pAM-FIB-R3/I5-transfected cells, reflecting the stronger activity of the cytomegalovirus (CMV) promoter in the former construct compared with the CBA promoter in the pAM-FIB-R3/I5 vector.
Viral vector production and brain injections
The pAM-DCA-EcoRI viral vector containing inverted terminal repeats (ITRs) from AAV serotype 2, and the coding sequence of FIB-R3/I5 or EGFP were packaged into a rAAV mosaic serotype 1/2 capsid, using the packaging plasmids pDPI and pDPII, as described. 37 Vector was harvested and purified using an iodixanol gradient; and in preparation for in vivo injections, titres of purified rAAV1/2 were determined using the characterized method of measuring the number of genomic copies (gc) per ml of purified rAAV1/2-EGFP or rAAV1/2-FIB-R3/I5, using quantitative polymerase chain reaction (qPCR). 38 These results were confirmed by assessing the ability of vectors to transduce cell lines in parallel. We transduced HT1080 cells with a serial dilution of purified rAAV1/2-EGFP in phosphate-buffered saline (PBS) and after 4 days visualized the comparative amount of cells that displayed green fluorescence. There was a good correlation between levels of green fluorescence in HT1080 cells and the difference in titres obtained by qPCR in different batches of rAAV1/2-EGFP over time (data not shown). As rAAV1/2-FIB-R3/I5 does not contain GFP, transduction of HT1080 cells could not be visualized, but with specific primers to amplify the FIB-R3/I5 DNA coding region, we were able to obtain titres on rAAV1/2-FIB-R3/I5 using qPCR. These titres were used to determine gc ml À 1 values and calculate injection titre and volumes.
An initial series of bilateral targeting injections of rAAV1/2-EGFP were made using 0.3 ml or 1 ml volumes, to test the optimal infusion volume and PVN co-ordinates. GFP fluorescence visualized in coronal brain sections through the region confirmed that the chosen co-ordinates facilitated the transduction of neurons in the PVN (data not shown). It was also evident that the optimal injection volume was 1 ml, as attempts to deliver 0.3 ml injections produced inconsistent results.
In vivo functional test of R3/I5 gene delivery vector The effect on food intake (feeding) and body weight of acute injections of relaxin-3 and R3/I5 peptides into the hypothalamus has been well-characterized (see Introduction). In this study, we The vector was first tested in an in vitro assay to ensure it was able to produce bioactive peptide. It was then used for in vivo studies to test the function of R3/I5. (e) pAM-EGFP does not contain the FIB signal peptides and was used as a negative control for in vivo studies and to localize the target site for injections. b-Gal, b-galactosidase.
wanted to test the long-term effects of R3/I5 expression in the hypothalamus. Therefore, 1 ml of rAAV1/2 (5.0 Â 10 11 viral particles per ml) was infused bilaterally into the PVN of rats (cohort 1). Control rats received an infusion of rAAV1/2-EGFP and importantly expression of GFP via rAAV vectors in the PVN of rats has been shown to have no effect on body weight and feeding. 39 Experimental rats received an infusion of rAAV1/2-FIB-R3/I5 with a 1:10 dilution of rAAV1/2-EGFP, to assist in localization of the injection site; this is the same equivalent dose of genomic copies of rAAV1/2 that the control rats received.
Food intake and body weight were monitored daily 8 days before the surgery period and then daily up to days 56 and 57 post-infusion, respectively. The body weights of the control and experimental rats were not significantly different before surgery and both groups of rats displayed a similar decrease in body weight gain and food intake for the first days after surgery, but all rats returned to their pre-surgery weight within 3 days after rAAV1/2 injection (Figure 4a ). The FIB-R3/I5-treated rats began to display an increase in body weight compared with control rats from day 8 post-infusion, correlating with the predicted time at which the viral transgene would reach its highest level of expression. Body weight continued to increase, but the mean body weight difference diverged between the groups, with a definitive separation from day 27 post-infusion through to the end of the observation period. In a two-way repeated measures . rAAV1/2-FIB-R3/I5 injection into the PVN of rats increased body weight and food intake, compared with rAAV1/2-EGFP 'control' injections. (a) Mean body weights of rats from the pre-surgery period to 57 days post-surgery. Body weights of both groups tracked closely in the pre-surgery period, followed by a decrease over the surgery period with all rats returning to their starting weights a few days after surgery. At B7 days after surgery, when R3/ I5 expression is predicted to be high, the rAAV1/2-FIB-R3/I5 group began to display an increase in body weight compared with the control group. By day 41, this difference reached significance and the body weight of the R3/I5-treated rats continues to increase until the end of the experiment. *Po0.05; # Po0.01 (b) The average food intake closely matches the body weight data, with no difference in average food intake pre-surgery; some fluctuation during/after the surgery period followed by a sustained increase in food intake in the rAAV1/2-FIB-R3/I5 group from day 7 post-infusion. This increase in 24 h food intake fluctuates about a mean baseline of 5.09 g ( ± 0.183 g) and the increase is sustained over the total time measured. Data are presented as mean±s.e.m. (n ¼ 8/7 per group, respectively),
analysis of variance, this difference first reached significance at day 41 (Po0.05). From day 47 the significant difference in body weight of the R3/I5 group compared with the control group (Po0.01) was maintained until the end of the study. In an independent statistical analysis, which takes into account the nonlinear change in weight over time regardless of treatment, we made an overall comparison between the two groups for body weight gain in the post-surgery period (day 8 onwards). We fitted the data using a nonlinear regression, which employed a quadratic line fit, and there was a significant difference between the two curves (Po0.001). At the completion of the study, rAAV1/ 2-FIB-R3/I5 rats had a B23% higher cumulative body weight gain compared with rAAV1/2-EGFP control rats.
Daily food intake was not different between the groups presurgery, but there were some fluctuations in food intake around the separate surgery days. However post-surgery, rAAV1/2-FIB-R3/ I5-injected rats demonstrated increased food intake compared with rAAV1/2-EGFP control rats from day 7 after rAAV1/2-FIB-R3/I5 infusion (day 8; Figure 4b ), again correlating with the anticipated maximal production of the transgene. This increase was sustained to the end of the study. This increase in 24 h food intake fluctuated about a mean baseline of 5.61 g (±0.18 g) from day 8 post-intervention. There was a significant interaction between treatment and food intake (P ¼ 0.0048), while there was no interaction between time and treatment (P ¼ 0.996), indicating that the effect of treatment on food intake over time was significant and constant. This sustained food intake increase in the FIB-R3/I5 rats is presumed to underlie the sustained increased weight gain in these rats. At the time of death, a measurement of blood glucose levels revealed no difference between FIB-R3/I5-treated and control EGFP-treated rats (data not shown).
Effect of rAAV vectors on behaviour
General locomotor activity of rAAV1/2-FIB-R3/I5-and rAAV1/2-EGFP-injected rats was assessed in locomotor chambers in 3 Â 1 h sessions during the light phase, over 3 consecutive days. There was no marked difference in the locomotor activity of the two groups of rats on any of the test days. The floor plane distance, number of floor plane moves and the time spent moving was the same for the control and FIB-R3/I5 groups, and the rats appeared to be similarly aroused with no significant difference in vertical plane moves (Figures 5a-d) . Unaltered locomotor activity suggests that chronic hypothalamic expression of EGFP and R3/I5 does not affect the general health of the rats.
Post-mortem assessment of viral injection targeting
The correct targeting of the AAV injections to the hypothalamus (and the PVN region) in cohort 1 rats was verified at the end of the experiment by the localization of GFP immunofluorescence in relation to OT immunostained neurons ( Figure 6 ). A series of six coronal sections was used to compare OT staining and GFP fluorescence, and another series was used to examine the GFP expression profile. A common observation in experimental and control rats was that neurons transduced by rAAV1/2-EGFP were primarily those surrounding OT-positive PVN neurons (see Figure 6 ). Some neurons among the clusters of OT-stained cells were transduced by rAAV1/2-EGFP (Figure 6f ), but it was mainly surrounding neurons that appeared transduced (Figures 6b, d and e).
Although there was some variability in the injection sites, all rats in the experimental groups displayed GFP fluorescence in close proximity to OT-containing neurons in PVN (n ¼ 8, rAAV1/2-EGFP and n ¼ 7, rAAV1/2-FIB-R3/I5). One experimental rat had received a unilateral injection and it was excluded from further group analysis. However, when analysed separately, its body weight fell between the control and rAAV1/2-FIB-R3/I5 group curves, indicating a potential partial dosing effect (Figure 7 ). Given the clear phenotype produced of increased food intake and body weight, the rAAV1/2-FIB-R3/I5 is presumed to produce a sufficiently high local concentration of peptide to influence PVN neurons expressing RXFP3. Effects of chronic FIB-R3/I5 production on hypothalamic gene expression levels Immunohistochemical analysis of the R3/I5 content and localization in rAAV-infused brain tissue was limited by the current unavailability of an antibody that can detect R3/I5 peptide. In lieu of direct detection of the peptide, to confirm expression of the FIB-R3/I5 transgene, a separate cohort of rats was infused with rAAV1/2-EGFP (n ¼ 8) or rAAV1/2-FIB-R3/I5 (n ¼ 12) and after a chronic period of expression (B12 weeks), we analysed the hypothalamic level of FIB-R3/I5 mRNA, as well as the relative levels of mRNA encoding RXFP3 and several hypothalamic peptide genes we hypothesized may be altered as a result of chronic activation of RXFP3 in the PVN.
At 3 months post-infusion, total RNA was extracted from a hypothalamic tissue sample, containing the PVN and arcuate nucleus, as well as surrounding anterior, lateral and posterior hypothalamus. First, we measured the level of FIB-R3/I5 transgene mRNA expression in all rats. In all, 9 out of /12 rats displayed a range of high levels of FIB-R3/I5 expression when normalized to the group mean expression levels ( Figure 8a ). As anticipated, transgene expression in the rAAV1/2-GFP group were not different from background, and in the rAAV1/2-FIB-R3/I5 group, two rats had transgene expression levels comparable to background levels, indicating likely mis-targeted injections. Also, one rAAV1/2-FIB-R3/I5-infused rat had low transgene expression (DC T fell outside the 95% confidence interval of the FIB-R3/I5 rats). We also tested GFP mRNA expression in the FIB-R3/I5 rats as they were also injected with a 1:10 dilution of rAAV1/2-EGFP, and the low GFP levels in these same three rAAV1/2-FIB-R3/I5-treated rats further suggested incorrect injections (data not shown). Hence, these rats were excluded from all subsequent analyses. These data indicate that the transgene mRNA is expressed over the course of the experiment and up to 3 months post-infusion.
There was no significant difference in RXFP3 mRNA levels in the control and FIB-R3/I5 groups after up to B12 weeks of chronic Levels of mRNA transcripts encoding three neuropeptides that are expressed in neurons of the arcuate nucleus and having a major role in regulating feeding, POMC, NPY and AgRP, 40, 41 were assessed and their mRNA levels were not significantly different between the two groups (Figures 8c-e) . Expression of the reproductive hormone, GnRH, was also investigated, as it has been reported that relaxin-3 altered GnRH secretion in GT1-7 cells in vitro. 19 Although the difference in relative fold change of GnRH mRNA expression between groups did not reach statistical significance (P ¼ 0.154), there appears to be a trend for increased GnRH mRNA levels in FIB-R3/I5 rats compared with control rats (Figure 8f) .
Finally, levels of mRNA transcripts encoding the neuropeptide hormones, OT and arginine-vasopressin (AVP), were also assessed. These hormones have a major role in osmotic and metabolic homoeostasis and related behaviours. 42, 43 The relative expression of AVP mRNA was reduced in rAAV-FIB-R3/I5-treated rats by B25% (P ¼ 0.051), whereas OT mRNA was markedly reduced by B50% (Po0.005) in the rAAV-FIB-R3/I5-treated group relative to control levels (Figures 8g and h ).
Body composition of rAAV1/2-infused rats Daily food intake and body weight of a second cohort of rats was monitored for 5 days pre-rAAV infusion and then for 10 days postinfusion; rats were handled regularly over the course of 2 months and then for the last 14 days of the study, their body weight and daily food intake was again measured. As observed previously, there was a significant interaction between treatment and food intake for these post-infusion observation periods (P ¼ 0.014), and no significant interaction between time and treatment (P ¼ 0.715). Hence, the increased food intake of rAAV1/2-FIB-R3/I5 rats compared with control rats was present at both the initial and the final stages of the experiment. Similarly, we analysed the body weight data as outlined for cohort 1 by fitting the data using a nonlinear regression, which employed a quadratic line fit. This analysis confirmed a significant difference between the rAAV1/2-FIB-R3/I5 and rAAV1/2-EGFP body weight curves (Po0.05).
At 3 days before brain tissue was collected for subsequent RNA analysis, all rats underwent assessment in an Echo-MRI Body Composition Analyser (Echo-MRI, Houston, TX, USA) to determine any difference in body composition between groups. The data obtained indicated that there was no significant difference between groups in fat, lean mass and total water (g), determined as a percentage of body weight ( Figure 9 ).
DISCUSSION
A major goal of this study was to establish a viral vector system to express the relaxin-3 agonist, R3/I5 in vivo, and chronically modulate RXFP3 activity in the hypothalamus of the rat. The relaxin-3 neuropeptide system has been highly conserved from fish through to mammals and studies in rodents implicate relaxin-3/RXFP3 signalling in many neurobiological processes, including arousal, stress and feeding. 4, 11, 13, 44 Importantly, the involvement of the relaxin-3 receptor, RXFP3, in these behaviours offers a potential therapeutic target to modulate aberrant activity of these systems in related disease states. To gauge the pharmacological applicability of modulating this peptide-receptor system, studies that investigate the effects of chronic modulation of RXFP3 are vital. Although relaxin-3-and RXFP3-knockout mouse strains are being used to study the neurobiological impact of permanently interrupting this receptor-ligand interaction in the brain, 4 these models do not mimic chronic drug treatment paradigms and there is the potential for developmental compensation in neurotransmission in whole-of-life gene deletion mice. The rat has been used extensively in pharmacological studies completed thus far to investigate relaxin-3 function. Furthermore, the gene encoding RXFP4 is a pseudogene in the rat, which is therefore a useful model for studying specific effects of RXFP3 modulation using the selective agonist, R3/I5, which does not activate the other relaxin family receptors, RXFP1 and RXFP2. Acute peptide injections in rats have highlighted the potential behavioural implications for endogenous relaxin-3 signalling. Here we describe the development of a viral vector system that chronically expresses R3/I5 in adult rat brain and that will allow us to study the various behaviours in which the relaxin-3/RXFP3 signalling has been implicated.
The first challenge in developing viral-mediated expression of R3/I5 was the complex structure of the peptide and the likely requirement for C-chain cleavage to produce a bioactive peptide. We therefore first tested the activity of mouse pro-relaxin-3 and as predicted it displayed very poor activity at RXFP3. Importantly, the low activity was not due to species differences in sequence or structure, as mature mouse relaxin-3 is equipotent to human relaxin-3. 45 The lack of activity of the pro-hormone is predictable because relaxin-3 analogues with alterations in the C terminus of the B-chain lack receptor activity, providing further confirmation that a free C terminus is required for full biological activity. 46 For our viral constructs, we had to ensure that cleavage of the C-peptide of the transgene product would occur in vivo, so we used an expression construct shown to direct the expression of cleaved R3/I5 in vitro. 17 This construct utilizes the native furin site at the B/C junction and an engineered site at the C/A junction, and when expressed with furin in vitro, cleaved bioactive R3/I5 is produced. However, for expression in vivo it was not feasible to co-express furin, so to ensure the correct processing of R3/I5 in vivo, we used an rAAV system developed for the local expression of peptides in neurons. 25 This viral system uses an rAAV1/2 vector to target specifically neurons in conjunction with the FIB secretory signal sequence fused to the peptide coding region of interest. The presence of an FIB signal peptide ensures that the protein linked to this signal sequence is shunted down this pathway and secreted. An added benefit of this system is that transduced neurons secrete the peptide locally (that is, in the Figure 7 . Cumulative body weight gain of rAAV1/2-FIB-R3/I5-treated rats is greater than that of rAAV1/2-EGFP-infused rats over the course of the 8-week experiment. One rat received a unilateral infusion of rAAV1/2-FIB-R3/I5 and was excluded from statistical analysis of group body weight gain and food intake. However, the body weight of this rat lies between those of the R3/I5 group and the control GFP group. One rat in the control group had a body weight in the range of the FIB-R3/I5-infused rats and one rat in this group had a cumulative body weight gain in the range of the control rats.
region of their soma), and enable targeting of peptide expression to the region adjacent to the viral injection site.
Importantly, we demonstrated that this viral vector was able to direct the production of high levels of secreted bioactive R3/I5 in vitro. HEK-293T cells transfected with the viral vector pAM-FIB-R3/I5 and furin directed the expression of bioactive R3/I5 peptide. We have previously shown that HEK-293T cells do not contain adequate levels of furin to cleave the C-peptide from pro-relaxin when it is produced recombinantly in these cells. 35 The amounts of peptide produced were slightly lower than from the pCMVSport-R3/I5 vector, but this was expected as this vector contains the CMV promoter, rather than the CBA promoter present in the pAM construct. The CBA promoter is better suited to long-term in vivo applications, as it is less likely to be silenced by host transcriptional inactivation, as reported for some CMVdriven viral vectors. 47, 48 The CBA-driven transgene expression is more than adequate for producing peptide at levels that can induce a physiological effect in vivo. 30 We proceeded to test the in vivo effects of the peptide R3/I5 being expressed by the pAM-FIB-R3/I5 construct. At the outset, we believed it might be technically difficult to measure levels of secreted R3/I5 peptide production in vivo, and thus attempted to detect R3/I5 production using a polyclonal relaxin-3 B-chain antibody; however, this approach was not sensitive enough to detect the constitutively secreted peptide. We therefore decided to validate this expression system by utilizing a previously identified phenotype that is easily measured, such as feeding and body weight, and subsequently to assess peptide transgene mRNA expression. The effect of relaxin-3 on feeding in rats has been studied extensively in studies of acute relaxin-3 and synthetic R3/I5 administration intracerebroventricularly and/or directly into the hypothalamus. 13, 49 A subchronic treatment over 14 days with relaxin-3 administered intracerebroventricularly via mini-pump infusion has also been completed. 34 Each of these studies demonstrated that relaxin-3 or R3/I5 administration robustly increases feeding in rats. On this basis, feeding provides an ideal behavioural test for the purpose of this study. The PVN region of the hypothalamus was chosen as the target site because it contains a high density of RXFP3 and relaxin-3 administration into the region increased feeding. 20 In our first cohort of rats in which the PVN was transduced with rAAV1/2-FIB-R3/I5 or rAAV1/2-EGFP (control), we measured body weight and food intake daily for a period commencing 8 days presurgery until B8 weeks after surgery. Most notably, rats treated with rAAV1/2-FIB-R3/I5 demonstrated a sustained increase in food intake from 7 days post-injection, which coincided with the anticipated highest transgene expression produced from an rAAV1/2 vector. 47 This sustained increase in daily food intake Figure 8 . Effect of an rAAV1/2-FIB-R3/I5 or rAAV1/2-EGFP (control) injection into the PVN on levels of mRNA encoding the transgene (a) FIB-R3/ I5; the cognate relaxin-3 receptor (b) RXFP3 and (c-h) several hypothalamic peptides. There were no significant differences in the levels of transcripts for (c) POMC, (d) NPY, (e) AgRP and (f ) GnRH in the two groups. In contrast, the level of mRNA expression of OT (g) and vasopressin (h) was reduced in rAAV-FIB-R3/I5-treated rats (**Po0.005 and P ¼ 0.051, respectively) compared with control. Data are presented as mean ± s.e.m., n ¼ 8-9 rats per group.
resulted in a gradual larger increase in body weight of rats in the R3/I5 group compared with those in the control group. This divergence in incremental weight gain was evident by day 27 after vector infusion and continued to increase throughout the observation period, and the FIB-R3/I5 rats gained B23% more weight than control rats. The consistent and sustained increase in body weight and food intake observed after expression of rAAV1/ 2-FIB-R3/I5 in the hypothalamus suggests that there is adequate endogenous furin to process pro-R3/I5 and that the virus expressed peptide for B8 weeks with no apparent desensitization of RXFP3 signalling. There was no change in general locomotor activity of the treated rats during the light cycle, which indicates that R3/I5 activation of hypothalamic RXFP3 may specifically affect feeding and body weight. However, as hypothalamic RXFP3 activation may alter circadian patterns of locomotor activity, it will be of interest to assess acute and longer term rats' locomotor activity patterns during the dark cycle.
The slightly variable distribution of GFP expression surrounding OT neurons in the PVN may be responsible for a 'dosage effect' in the experimental group dependent on the number of viraltransduced cells and their proximity to RXFP3-expressing neurons. Variations in targeting have been observed in earlier studies of the effects of viral expression of peptide agonists on feeding. 24, 50 However, importantly only one rAAV1/2-FIB-R3/I5-treated rat (that was smaller than the others) demonstrated body weight gain in the same range as GFP-treated rats (Figure 7) . In addition, a rat that received a unilateral injection and was excluded from the R3/I5 group analyses demonstrated body weight gain values between the mean values for the R3/I5 and control groups, suggesting it received a partial dose of peptide (Figure 7 ). McGowan and co-workers 13, 20 have shown that both central intracerebroventricular injections and intra-PVN injections result in a significant increase in food intake 1 h post-administration, suggesting that a clear phenotype can be produced as long as the injections are in the vicinity of the PVN. The distance that R3/I5 diffuses following secretion from transduced neurons is currently unknown; however, our results suggest that the peptide is accessing RXFP3 present on hypothalamic PVN neurons, particularly given that we observed changes in OT and AVP mRNA expression in these neurons, which we believe also express RXFP3. 6 We observed day-to-day variation in food intake in both groups, which was quite pronounced the day after home cage boxes/litter were changed, indicating an influence of environmental factors. To compare food intake between groups while taking these daily fluctuations into account, we examined the difference in average food intake between the control GFP-and FIB-R3/I5-infused groups and observed that a constant increase in food intake of B5 g per day for FIB-R3/I5-infused rats was sustained throughout the experiment. In studies in which relaxin-3 was administered intracerebroventricularly via an osmotic minipump over 14 days, the average daily increase in food intake was B5-10 g. 34 A similar increase in food intake was also observed following twice-daily intra-PVN injections of relaxin-3 for 7 days. 20 The slightly higher levels of daily food intake in rats in these pharmacological studies may be due to the administration of a higher dose of peptide than is produced chronically by rAAV. We found no difference in blood glucose level between the rAAV1/2-FIB-R3/I5 and control group.
In a second cohort of rats infused with rAAV1/2-FIB-R3/I5, we examined body composition just before the completion of the study and found no significant difference in the body fat, lean mass and total water content of FIB-R3/I5 compared with control rats. These data are consistent with an earlier subchronic relaxin-3 infusion study, in which there was no significant difference between epidydymal fat mass (white adipose tissue) and interscapular brown adipose weights and mRNA expression of the brown adipocyte marker, UCP-1, in rats injected with relaxin-3 iPVN over 7 days (pair-fed or ad libitum fed) compared with control. 20 Previous studies in which similar rAAV-based methods have been used to express the peptides NPY or AgRP in the PVN observed more robust increases in cumulative body weight compared with those observed after R3/I5 in this study. 51, 52 By day 50 post-infusion of rAAV-NPY or rAAV-AgRP, rats gained B65% and B125% more body weight than controls, respectively. 51, 52 These findings are consistent with data which indicate that these peptides have a direct role in control of feeding and obesity and an expected stronger action compared with the B23% gain in rAAV1/2-FIB-R3/I5-infused rats over a similar time course. It has also been established that NPY and AgRP cause large changes in body weight by increased feeding and reduced energy expenditure. 53, 54 McGowan et al. 20 demonstrated that there were no acute effects of intracerebroventricular relaxin-3 administration on a number of metabolic parameters such as VO 2 , respiratory exchange rate and ambulatory activity. Also, pair-fed animals injected with relaxin-3 iPVN over 7 days had the same cumulative body weight change at day 7, suggesting no significant effect of relaxin-3 iPVN on energy expenditure. 20 Notably, while daily food intake in rAAV-NPY-infused rats reached a maximum of B12 g per day above control, by day 20 the magnitude of the difference declined and had returned to control levels by day 40, and remained at this level until the end of the study (day 50). 51, 52 In early studies, NPY infusion into the PVN of rats, twice daily for 10 days, resulted in an increase of B20 g per day compared with control and the effect was sustained for the 10-day period. 55 Thus, while NPY in the PVN elicits a larger feeding response and a larger cumulative body weight gain than R3/I5 or relaxin-3, the relative difference in daily food intake in the acute NPY administration and the rAAV-NPY studies is comparable to the daily food intake differences observed in the rAAV-R3/I5 and acute relaxin-3 injection studies. The neuron-specific enolase promoter was utilized in the rAAV NPY and AgRP studies, but neuron-specific enolase and the CBA promoter used in this study display comparably high levels of transgene expression, 47 with some reports that the CBA promoter may drive higher levels of transgene expression than the neuron-specific enolase promoter. 56 Thus, this is unlikely to be the cause of the observed differences and it is more likely a result of the different distributions and mechanisms of action of the individual peptides. For example, actions of NPY produced by hypothalamic neurons have been strongly linked to obesity, whereas relaxin-3 produced by brainstem neurons may not primarily be a 'feeding peptide'; 57 however, it may attenuate feeding responses under certain physiological conditions without producing major changes in energy expenditure. The activity profile of these two peptides is quite different, but in assessing their potential for use as therapeutic agents in the treatment of feeding disorders, it may be preferential to produce a sustained modest alteration in food intake, with minimal receptor desensitization, as observed in the rAAV-FIB-R3/I5-infused rats. In addition, as NPY has five receptors through which it can mediate effects on feeding and other neural networks, [58] [59] [60] its potential as a therapeutic agent may be more restricted.
In a second cohort of rats, we confirmed the stimulatory effect of hypothalamic RXFP3 activation by R3/I5 on food intake and body weight, and importantly we conducted gene expression studies in which we confirmed the presence of high levels of expression of the FIB-R3/I5 transgene, over the course of 12 weeks post-infusion, with no accompanying desensitization at the mRNA level of the receptor, RXFP3, in the hypothalamus. We also assessed the levels of mRNA transcripts encoding the major hypothalamic feeding peptides, NPY, AgRP and POMC (see review), 61 which were not altered. These data may reflect our complementary physiological findings, which indicate that it is unlikely that major changes in energy expenditure are contributing to the differences in body weight observed. Downregulated hypothalamic OT, and to a lesser extent AVP, may present a distinct mechanism through which RXFP3 activation increases feeding and body weight. Central OT has been previously reported to suppress food intake and body weight, and complementary studies have shown that antagonism of central OT stimulates feeding. [62] [63] [64] Inhibition of this anorexigenic peptide may be responsible for the increase in food intake observed in these studies. The mechanism through which OT does this has not been very well characterized and warrants further investigation. In addition, results from this study as well as previous studies of the effects of intracerebroventricular injections of relaxin-3 agonists have demonstrated no apparent deleterious side effects of targeting RXFP3 in the brain. 13 Therefore, RXFP3 may represent a valid therapeutic target for modulation of feeding and further studies into the mechanism of action of relaxin-3 on feeding are warranted.
In conclusion, we have developed a robust rAAV-based method to enable studies of the effect of chronic RXFP3 activation within specific brain areas on aspects of normal physiology and behaviour. This approach will be particularly relevant for further investigations of modalities postulated to be regulated by relaxin-3 signalling, including arousal, stress and spatial and emotional cognition. 14 
MATERIALS AND METHODS
Cloning plasmids for gene product delivery
The coding region of the peptide, R3/I5, containing the native relaxin-3 C-peptide and an engineered furin cleavage site at the C/A-chain junction from the vector pCMVSport1 (kindly provided by Dr Changlu Liu, Johnson & Johnson Pharmaceutical Research and Development LLC, San Diego, CA, USA) 17 was cloned into the viral vector pAM-DCA-EcoRI-EGFP (kindly provided by Dr Verena Wimmer, Florey Institute of Neuroscience and Mental Health, Melbourne, VIC, Australia) by a three-stage process to produce pAM-FIB-R3/I5. The coding region of R3/I5 was PCR amplified from the pCMVSport1 vector using a forward primer introducing a SmaI site (5 0 -CATCATCCCGGGCAGCGCCTTACGGGGTC-3 0 ) and a reverse primer introducing a NotI restriction site (5 0 -GAGAGGCGGCCGCTTAGCAAAGAGC ACTCA-AATCAGTCATGGAAC-3 0 ). The PCR product (R3/I5 344 bp) was ligated into Bluescript II KS ( À ) as an intermediate vector to obtain the restriction sites needed for cloning into the TR-CBA-FIB-GFP construct (a generous gift from Professor Thomas McGown, University of North Carolina Gene Therapy Center, Chapel Hill, NC, USA) 25 to produce the FIB-R3/I5 sequence. Bluescript KS( À )R3/I5 was first digested with NotI (37 1C) followed by SmaI (25 1C), and then the 5 0 end was dephosphorylated with thermosensitive alkaline phosphatase (Promega, Madison, WI, USA) to ensure that there was no re-ligation of the vector. The viral vector TR-CBA-FIB-GFP was restriction digested with AleI and NotI high fidelity (NEBiolabs, Ipswich, MA, USA), and the cut vector was then incubated with the enzyme thermosensitive alkaline phosphatase, followed by clean up using ethanol precipitation. The 344 bp insert was then gel purified using a Wizard spin column gel purification kit (Promega). The FIB-R3/I5 sequence was then cloned into pAM-DCA-EcoRI-EGFP, a plasmid with ITRs from AAV2, which has been used in our laboratory to successfully transduce neurons after injection in rats. 65 The vector pAM-DCA-EcoRI-EGFP vector was digested with SmaI and shown to have intact ITRs; thus, the EGFP was excised using a double digestion of BamHI and NotI, followed by treatment with thermosensitive alkaline phosphatase to dephosphorylate the 5 0 end and prevent re-ligation. FIB-R3/I5 was excised from the TR-CBA-FIB construct with BamHI and NotI and ligated into the pAM vector to produce pAM-FIB-R3/I5.
All ligations were performed at 16 1C overnight with T4 ligase and ligation products were transformed into DH5a cells or SURE2 (Stop Unwanted Rearrangement Events; Stratagene, Santa Clara, CA, USA) supercompetent cells for viral constructs and plated onto Lysogeny broth agar plates containing ampicillin. Colonies were selected and DNA minipreps were performed followed by digestion analysis to confirm inserts. All clones were sequenced on both strands of DNA to ensure there were no PCR errors introduced into the DNA sequence. Final clones with the correct sequences were selected and DNA was produced on a large scale and stored at À 20 1C for use in rAAV production.
Cell culture and transfection HEK293T cells (ATCC no. CRL-1573; American Type Tissue Culture Collection, Manassas, VA, USA) and CHO-KI cells stably transfected with RXFP3 were maintained in 50% Dulbecco's modified Eagle's medium and 50% Ham's F12 (Gibco-BRL, Invitrogen, Melbourne, VIC, Australia), supplemented with 10% fetal bovine serum, 100 mg ml À 1 penicillin, 100 mg ml À 1 streptomycin and 2 mM L-glutamine. 66 CHO-KI cells stably transfected with RXFP3 were selected with Geneticin (Invitrogen, Melbourne, VIC, Australia). HEK293T cells were seeded on six-well plates at 400 000 cells per well the day before transfection. Transient co-transfection of HEK293T cells was performed using Lipofectamine 2000 (Invitrogen) as per the manufacturer's instructions. A total of 10 mg of DNA with 10 ml of Lipofectamine was made up in serum-free media, Opti-MEM (Invitrogen) and transfected per 1 100 000 cells. Lipofectamine/DNA complexes were incubated at room temperature (RT) for 20 min and then added to the cells. At 48 h after transfection, conditioned medium was collected and stored at À 20 1C.
Receptor signalling (reflecting altered cAMP levels) was assessed using a pCRE reporter gene assay as described. 27 Briefly, CHO-KI RXFP3 stable cells were seeded into 96-well plates at 26 000 cells per well and grown overnight. Cells were transfected with the pCRE b-galactosidase reporter plasmid the day before cell stimulation. 36 Transfected cells were incubated with 5 mM forskolin (Sigma-Aldrich, Sydney, NSW, Australia) and increasing concentrations (0.01-1000 nM) of synthetic H3 relaxin or R3/I5 (courtesy of Prof. John Wade, Florey Institute of Neuroscience and Mental Health) 27, 67 or recombinant mouse pro-relaxin-3, 27 or increasing dilutions of conditioned HEK293T media in complete Dulbecco's modified Eagle's medium and Ham's F12 (1:1000, 1:100, 1:50, 1:25, 1:10 and 1:5), for 6 h at 37 1C, after which, the media were aspirated and the cells were frozen and stored at À 80 1C overnight. The amount of cAMP-driven b-galactosidase expression was determined in each well as described. 27 All experiments were repeated at least three times with triplicate determinations within each assay. Data were analysed using Graphpad PRISM 5 (Graphpad Inc., La Jolla, CA, USA) and normalized against the 5 mM forskolin response. Results were plotted as mean ± s.e.m. of per cent normalized forskolin response.
rAAV production, purification and characterization Mosaic-coated rAAV1/2 was produced and purified as described. 37 Briefly, AAV293 cells (Stratagene) were maintained at 37 1C with 5% CO 2 in 15 cm dishes in Dulbecco's modified Eagle's medium (Gibco-BRL, Melbourne, VIC, Australia) supplemented with 10% fetal bovine serum (Gibco-BRL), (2%) 100 Â non-essential amino acids, (2%) 100 Â sodium pyruvate and (1%) penicillin/streptomycin (Gibco-BRL). Cells were maintained at 40-50% confluency for passaging, they were washed with warm PBS and split using trypsin/EDTA.
For preparative large-scale productions, 1.0 Â 10 7 cells were seeded in each of ten 15-cm culture dishes (Nalgene Nunc, Rochester, NY, USA), and the next day transfected with 50.5 mg DNA per plate. rAAV vector and helper plasmids, pDPI and pDPII, 68 were transfected in a 1:1 molar ratio of pAM-FIB-R3/I5 or pAM-EGFP with pDP1 þ pDP2, using the calcium phosphate method. 39 Media were replaced after 16 h, and then 72 h after transfection, cells were harvested in their medium, centrifuged and collected in 10 ml lysis buffer (150 mM NaCl, 50 mM Tris-HCl, pH 8.5) (1 ml per 15 cm plate). Viral particles were liberated using a series of five freeze-thaw cycles, by alternating between 37 1C and approximately À 80 1C. The lysate was then incubated with benzonase endonuclease (Sigma, Castle Hill, NSW, Australia) at a final concentration of 50 U ml À 1 for 1 h at 37 1C. Cell debris was pelleted via centrifugation and the supernatant containing rAAV was filtered through a 13 mm diameter 45 mm Acrodiscfilter (Millipore, Billerica, MA, USA) and subsequently loaded onto an iodixanol gradient for purification. The density gradients consisted of supernatant, 15, 25, 40 and 54% iodixanol from a 60% (w v À 1 ) iodixanol solution and OptiPrep (Sigma) in quickseal tubes (Hitachi, Seven Hills, NSW, Australia). After 1 h of ultracentrifugation (350 000 g av at 18 1C) in a P90AT rotor (Hitachi), the layer at the 54%/40% interface was extracted and concentrated using an Amicon centricon filter device (Millipore) and dialysed with PBS. A final volume of B250 ml was collected and then filtered through a 13 mm 22-mm filter unit (Millipore) and stored at 4 1C for titration and use. The titre in gc per ml was determined by qPCR using a SYBR Green Mastermix (Applied Biosystems, Melbourne, VIC, Australia) in a PE-ABI Prism 7700 Sequence Detection System version 1.9.1 (Applied Biosystems). 38 The qPCR primers used to detect GFP were forward, 5 0 -CTGACCCTGAAGTTCATCTGCACCAC-3 0 and reverse, 5 0 -TCCAGCAGGACCATGTGATC-3 0 (kindly provided by Dr Marijke de Backer, Rudolf Magnus Institute of Neuroscience, Utrecht University Medical Centre, Utrecht, the Netherlands) and those used to detect FIB-R3/ I5 were forward, 5 0 -GCGGCTGCTGCTGCTAG-3 0 and reverse, 5 0 -GTGAAGATGACTGCTCGGATGA-3 0 . Qualitative analysis of rAAV1/2-EGFP was conducted by infecting HT1080 cells and visualizing infectivity after 4 days. Briefly, HT1080 cells were maintained in DMEM (Gibco-BRL) supplemented with 10% fetal bovine serum (Gibco-BRL), 1% penicillin/streptomycin and 1% L-glutamine at 37 1C with 5% CO 2 and 85% humidity in a CO 2 water-jacket incubator (Forma Scientific, Marietta, OH, USA). Cells were maintained in 175 cm 2 flasks. Cells were plated at 80 000 per well in a 24-well plate containing coverslips coated in 0.01 mg ml À 1 poly-L-lysine (Sigma). The day after plating cells were transduced with a series of dilutions of purified rAAV1/2 maxiprep in PBS: 1 ml purified rAAV1/2, 1:10, 1:100, 1:1000, 1:10 000 and mock. On day 3, media were changed and the cells were left to grow for a further 48 h. On day 5, cells were washed once with warm PBS, then icecold 4% paraformaldehyde was added and subsequently the cells were fixed in the dark on ice for 10 min. Cells were washed again with PBS, and coverslips were mounted onto gelatin-coated slides using DAKO fluorescence mounting medium (DAKO, Glostrup, Denmark). Fluorescence was assessed on an Olympus IX fluorescence microscope (Olympus, Notting Hill, VIC, Australia).
Experimental animals
All experiments described were conducted with the approval of the Florey Institute Animal Welfare Committee and according to ethical guidelines issued by the National Health and Medical Research Council of Australia. All efforts were made to minimize the number of rats used and any discomfort or suffering. Male Sprague-Dawley rats (n ¼ 36; 250-300 g) were obtained from the Australian Research Centre (Canning Vale, WA, Australia) and maintained on a 12-h light/dark cycle, in single housing with free access to food and water.
Surgical procedures
For viral vector infusions, rats were initially anaesthetized with 4% isoflurane inhalation at 1 litre min À 1 in air and placed into a stereotaxic frame (Kopf Instruments, Tujunga, CA, USA). Anaesthesia was maintained with 2% isoflurane (0.2 l min À 1 in air) through an inhalation mask. Bilateral injections of rAAV1/2 (1 ml B5 Â 10 11 gc ml À 1 ) were made into the PVN (AP À 1.8 mm, ML þ 0.6 mm and À 0.6 mm, DV À 7.8 mm from bregma, according to the atlas of Paxinos and Watson. 69 Control rats received B5 Â 10 8 gc of rAAV1/2-EGFP (n ¼ 8/8 cohort 1/2), whereas experimental rats (n ¼ 8/12 cohort 1/2) received a 9:10 rAAV1/2-FIB-R3/I5 with a 1:10 dilution of GFP-expressing viral vector to assist with targeting (B4.5 Â 10 8 gc rAAV1/2-FIB-R3/I5 þ B5 Â 10 7 gc rAAV1/2-EGFP). Injections were made at a rate of 0.5 ml min À 1 via a pulled glass micropipette connected via an adaptor to 1/16 in OD and 0.007 ID PEEK tubing and a 10 Hamilton syringe mounted on an infusion pump (Harvard Apparatus, Holliston, MA, USA). The injector was left in place for 7 min and then drawn up 1 mm and left for 2 min to allow for any diffusion of rAAV from the injector, before the injector was fully withdrawn. After surgery, each rat received an injection of meloxicam (3 mg kg À 1 , subcutaneously). The incision was sutured and rats were allowed to recover for 7 days.
Behavioural and physiological testing
Feeding and body weight. Rats in cohort 1 were weighed daily between 0900 and 1100 h (that is, during their inactive/light phase). Daily food intake was carefully assessed by providing each rat with a pre-weighed amount of standard rodent chow (B100 g) and then weighing what remained 24 h later. Any uneaten food in the cage was also collected and weighed. Cumulative body weight data were analysed using two independent statistical analyses. Firstly, we conducted a two-way repeated measures analysis of variance with Bonferroni post-test of the raw data, and then we fitted a polynomial to the post-intervention data for both groups and compared the two resultant curves (PRISM 5, GraphPad Inc.). For cohort 2, body weight and daily food intake of rats were measured over 5 days before viral infusion, for 10 days post-infusion and for the final 14 days of the chronic expression study.
Locomotor cell. Motor activity of rats was tested over a 60 min period between 1000 and 1300 h on three consecutive days. Rats were placed in a 41 cm Â 41 cm Â 41 cm clear-walled locomotor cell (Tru Scan Photobeam Arena, E63-20; Coulbourn Instruments, Whitehall, PA, USA). Photobeam detectors tracked both horizontal and vertical movements over the course of the test. The TruScan 2.0 software (Coulburn Instruments, Whitehall, PA, USA) automatically determined the total distance travelled, the number of floor plane moves and the number of vertical plane entries. Data were analysed using a two-way analysis of variance (PRISM 5, GraphPad Inc.).
Echo-MRI body composition analyser
The body composition of rats in cohort 2 was analysed at the completion of the study using an Echo-MRI Body Composition Analyser for small animals (courtesy of Dr Michael Mathai, Victoria University, Melbourne, VIC, Australia). Rats were placed in a cylindrical tube that provided a sufficient level of restraint to prevent movement during the analysis. The cylinder was then placed in the Echo-MRI machine and the body composition of rats was analysed within 1-2 min. Each rat was then returned to its home cage. The Echo-MRI Body Composition Analyser provided measurements of body fat mass, lean mass, free water and total body water. Each rat was analysed at least twice to ensure reproducibility of results.
Perfusion fixation, tissue preparation and histological analysis Rats were killed by sodium pentobarbital injection (100mg kg À 1 , intraperitoneally), B1 ml of blood was collected via a heart puncture with a 16-gauge needle and transferred to heparinized tubes, and then each rat was perfused transcardially with B300 ml ice-cold PBS solution (PBS: 137 mM NaCl, 2.7 mM KCl, 11.2 mM Na 2 HPO 4 , 1.8 mM KH 2 PO 4 , pH 7.4), followed by B400 ml ice-cold 4% paraformaldehyde in PBS (pH 7.4). Blood was used immediately to measure the concentration of glucose using a MediSense TrueSense (MediSense, San Diego, CA, USA) blood glucose metre and electrodes. Brains were dissected and immersed in fixative for 1 h at 4 1C before cryoprotection in 30% sucrose in PBS at 4 1C. Brains were then frozen on dry ice and stored at À 80 1C. Coronal sections (40 mm) were cut in six series on a cryostat at À 16 1C (Cryocut 1800; Leica Microsystems, Heerbrugg, Switzerland) and collected into PBS immediately before immunohistochemical processing. One of the six series of sections was used for detection of GFP to confirm viral targeting. Sections were mounted on gelatin-chrom-alum-coated glass microscope slides and coverslips were mounted using Fluoromount (DAKO). Green fluorescence was visualized using an Olympus FV 1000 confocal microscope (Olympus Imaging, Melbourne, VIC, Australia).
For OT immunohistochemistry to help define the PVN region, one series of free-floating sections was washed with 3 Â PBS, then incubated overnight in PBS supplemented with 0.3% Triton X-100, 1% normal goat serum (NGS) and rabbit monoclonal OT antibody (1:5000; Millipore). Sections were washed for 3 Â 5 min with PBS and incubated for 30 min at RT in blocking solution (10% normal goat serum, 0.3% Triton X-100 in PBS) before being incubated for 2 h with secondary antibody, Alexa-594-conjugated goat anti-rabbit (1:200) (Invitrogen) in 1% normal goat serum and 0.3% Triton X-100 in PBS. Sections were gently agitated on an orbital shaker in a dark plate holder for 1 h at RT. After 3 Â 5 min washes with PBS, sections were transferred to glass microscope slides and coverslipped using fluorescence mounting medium (DAKO). Slides were stored in the dark at 4 1C.
Tissue collection for gene expression analysis
To isolate RNA for qPCR analysis, a second cohort of rats was killed by isoflurane inhalation overdose and decapitation 12 weeks after rAAV1/2-EGFP and rAAV1/2-FIB-R3/I5 injections. All surgical equipment was cleaned in 100% ethanol and, RNAse zap (Ambion, Melbourne, VIC, Australia), then dried and rinsed in DEPC-treated water and cooled on ice before use. Each brain was rapidly removed and placed in a ice-cold brain block. A hypothalamic slice containing the PVN and arcuate nucleus and surrounding hypothalamic areas was dissected and snap frozen over liquid nitrogen and stored at À 80 1C until use.
Total RNA was extracted using RNeasy Mini kits with genomic DNA eliminator (Qiagen, Melbourne, VIC, Australia) as per the manufacturer's protocol. For each sample, total RNA was reverse transcribed into cDNA using TaqMan Reverse Transcription reagents (Applied Biosystems) with random hexamers. Reverse transcription reactions were performed on a PCR Thermal Cycler Dice (Takara, Melbourne, VIC, Australia) using the following conditions 25 1C for 10 min, 42 1C for 30 min, 95 1C for 5 min and held at 4 1C. The cDNA products were stored at À 20 1C for subsequent use. All gene expression studies were conducted using qPCR performed on the PE-ABI Prism 7700 Sequence Detection System Version 1.9.1 (Applied Biosystems). Reactions were performed in 96-well plates and run using standard conditions: 2 min at 50 1C, 10 min at 95 1C and 40 cycles of 15 s at 95 1C and 1 min at 60 1C, with fluorescence measured after each cycle. Data were analysed using the 7500 Fast System Sequence Detection Software (Applied Biosystems).
Three different house-keeping genes (GAPDH, b-actin and HPRT1) were assessed for suitability of use in the hypothalamus, as described. 70 HPRT1 was the most stable and was used for all subsequent gene expression analyses using the primers: HPRT1 forward, 5 0 -CTAAGGCCAACCGTGAAAAG AT-3 0 and HPRT1 reverse, 5 0 -TCCACTTTCGCTGATGACAG-3 0 . To assess transgene expression (FIB-R3/I5 and EGFP) at the completion of the experiment, the primers designed to titre the rAAV were used (sequences outlined above). Determination of relative gene expression of RXFP3, NPY, AgRP, POMC, GnRH, AVP and OT was performed using the 2 À DDC T method as described. 71, 72 The primers were designed using Primer3 as outlined, 73 unless stated otherwise, and were as follows: RXFP3 forward, 5 0 . Briefly, qPCR was performed on n ¼ 8 control rats and n ¼ 12 FIB-R3/ I5-injected rats in triplicate for all genes assessed. A measure of 5 ml of cDNA was added to wells followed by master mix containing 12.5 ml SYBR Green Mastermix (Applied Biosystems), forward and reverse primers, and made up to 25 ml total volume with DNAse and RNAse free water. Optimized primer concentrations were used based on the results of primer efficiency and gene amplification experiments. Neuropeptide, receptor and GnRH expression data were compared by unpaired Student's t-test between control and treated groups.
